Corex cough syrup gets Cipla boost as Pfizer strikes exclusive India deal

Pfizer

Pfizer India has entered into an exclusive agreement with Cipla to market and distribute four of its legacy brands in India, including the popular Corex cough syrups, the US-headquartered pharma firm said on December 19, a move that will strengthen its presence in key therapy areas.

The agreement gives Cipla, which dominates India’s respiratory segment, the sole rights to sell and distribute the two Corex variants, Dx and LS , along with Dolonex (an NSAID), Neksium (a proton pump inhibitor), and Dalacin C (an oral antibiotic). Pfizer will continue to manufacture and supply the products.

The agreement is for a five-year period. Cipla said the agreement involves no upfront consideration and didn’t share financial terms of the deal.

“This partnership combines Pfizer’s innovation with Cipla’s deep distribution network to meet the needs of millions of patients,” said Meenakshi Nevatia, Country President at Pfizer India.

Cipla COO Achin Gupta called the tie-up a step toward “making strong brands even stronger”.

The deal marks the first collaboration between the two pharma giants in India, where Pfizer has operated for over 75 years.

Cipla, ranked third in India’s pharma market, expects the alliance to reinforce its footprint across respiratory and gastrointestinal segments.